Kaliumchlorid B. Braun (Potassium Chloride)

After intravenous infusion, potassium chloride dissociates into potassium and chloride ions. The potassium ions enter cells via the Na⁺/K⁺‑ATPase pump, raising extracellular potassium concentrations and normalising the electrochemical gradient required for nerve impulse transmission, muscle contraction and cardiac rhythm maintenance.

The dose of Kaliumchlorid B. Braun is determined by the prescribing clinician based on the patient’s current serum potassium level, renal function, and overall clinical condition. The prescriber calculates the required amount to safely raise potassium to the target range and selects an appropriate infusion rate.

Safety data for Kaliumchlorid B. Braun in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Kaliumchlorid B. Braun is an intravenous formulation, offering rapid correction of potassium deficits, which is advantageous over oral potassium salts when immediate repletion is required or when oral absorption is compromised. Oral preparations are slower and may cause gastrointestinal irritation, while the IV form allows precise dosing under clinical supervision.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and extreme temperature fluctuations. Do not freeze. Inspect the solution for particulate matter or discoloration before use, and follow aseptic techniques during preparation.

Kaliumchlorid B. Braun is administered intravenously. The solution is typically diluted in a compatible IV fluid and infused over a period determined by the prescribed dose and patient tolerance, often not exceeding 10 mEq per hour without cardiac monitoring. Administration must be performed by qualified healthcare personnel.

The most serious risks include severe hyperkalemia, which can lead to life‑threatening cardiac arrhythmias, and anaphylactic reactions. Rapid infusion or dosing errors may precipitate these events, so continuous cardiac monitoring and serum potassium checks are essential during therapy.

Patients with existing hyperkalemia (serum potassium >5.5 mmol/L), severe renal failure, or those receiving concurrent potassium‑sparing medications without close monitoring should avoid this product. Additionally, individuals with known hypersensitivity to potassium chloride or any excipients in the formulation should not receive it.